

Appendix A: Preferred Reporting Items for Systematic reviews and Meta-Analyses**extension for Scoping Reviews (PRISMA-ScR) Checklist**

SECTION	ITEM	PRISMA-ScR CHECKLIST ITEM	REPORTED ON PAGE #
TITLE			
Title	1	Identify the report as a scoping review.	1
ABSTRACT			
Structured summary	2	Provide a structured summary that includes (as applicable): background, objectives, eligibility criteria, sources of evidence, charting methods, results, and conclusions that relate to the review questions and objectives.	2-3
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known. Explain why the review questions/objectives lend themselves to a scoping review approach.	4-5
Objectives	4	Provide an explicit statement of the questions and objectives being addressed with reference to their key elements (e.g., population or participants, concepts, and context) or other relevant key elements used to conceptualize the review questions and/or objectives.	5
METHODS			
Protocol and registration	5	Indicate whether a review protocol exists; state if and where it can be accessed (e.g., a Web address); and if available, provide registration information, including the registration number.	N/A
Eligibility criteria	6	Specify characteristics of the sources of evidence	5-6

SECTION	ITEM	PRISMA-ScR CHECKLIST ITEM	REPORTED ON PAGE #
		used as eligibility criteria (e.g., years considered, language, and publication status), and provide a rationale.	
Information sources*	7	Describe all information sources in the search (e.g., databases with dates of coverage and contact with authors to identify additional sources), as well as the date the most recent search was executed.	6
Search	8	Present the full electronic search strategy for at least 1 database, including any limits used, such that it could be repeated.	Appendix B
Selection of sources of evidence†	9	State the process for selecting sources of evidence (i.e., screening and eligibility) included in the scoping review.	6-7
Data charting process‡	10	Describe the methods of charting data from the included sources of evidence (e.g., calibrated forms or forms that have been tested by the team before their use, and whether data charting was done independently or in duplicate) and any processes for obtaining and confirming data from investigators.	7
Data items	11	List and define all variables for which data were sought and any assumptions and simplifications made.	N/A
Critical appraisal of individual sources of evidence§	12	If done, provide a rationale for conducting a critical appraisal of included sources of evidence; describe the methods used and how this information was used in any data synthesis (if appropriate).	7
Synthesis of results	13	Describe the methods of handling and summarizing the data that were charted.	7

SECTION	ITEM	PRISMA-ScR CHECKLIST ITEM	REPORTED ON PAGE #
RESULTS			
Selection of sources of evidence	14	Give numbers of sources of evidence screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally using a flow diagram.	7
Characteristics of sources of evidence	15	For each source of evidence, present characteristics for which data were charted and provide the citations.	7-9
Critical appraisal within sources of evidence	16	If done, present data on critical appraisal of included sources of evidence (see item 12).	Appendix D
Results of individual sources of evidence	17	For each included source of evidence, present the relevant data that were charted that relate to the review questions and objectives.	8-19
Synthesis of results	18	Summarize and/or present the charting results as they relate to the review questions and objectives.	8-19
DISCUSSION			
Summary of evidence	19	Summarize the main results (including an overview of concepts, themes, and types of evidence available), link to the review questions and objectives, and consider the relevance to key groups.	20-21
Limitations	20	Discuss the limitations of the scoping review process.	21
Conclusions	21	Provide a general interpretation of the results with respect to the review questions and objectives, as well as potential implications and/or next steps.	23
FUNDING			
Funding	22	Describe sources of funding for the included sources	24

SECTION	ITEM	PRISMA-ScR CHECKLIST ITEM	REPORTED ON PAGE #
		of evidence, as well as sources of funding for the scoping review. Describe the role of the funders of the scoping review.	

JBI = Joanna Briggs Institute; PRISMA-ScR = Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews.

* Where *sources of evidence* (see second footnote) are compiled from, such as bibliographic databases, social media platforms, and Web sites.

† A more inclusive/heterogeneous term used to account for the different types of evidence or data sources (e.g., quantitative and/or qualitative research, expert opinion, and policy documents) that may be eligible in a scoping review as opposed to only studies. This is not to be confused with *information sources* (see first footnote).

‡ The frameworks by Arksey and O'Malley (6) and Levac and colleagues (7) and the JBI guidance (4, 5) refer to the process of data extraction in a scoping review as data charting.

§ The process of systematically examining research evidence to assess its validity, results, and relevance before using it to inform a decision. This term is used for items 12 and 19 instead of "risk of bias" (which is more applicable to systematic reviews of interventions) to include and acknowledge the various sources of evidence that may be used in a scoping review (e.g., quantitative and/or qualitative research, expert opinion, and policy document).

From: Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. *Ann Intern Med.* 2018;169:467–473. doi: [10.7326/M18-0850](https://doi.org/10.7326/M18-0850).

Appendix B: Search Terms

Database	Key Words
Ovid Medline	<p>Telemedicine/ OR Mhealth OR m-health OR e-notification* OR ((digital or mobile) adj health) OR on?line OR internet OR app OR application OR ((cellular or mobile or smart) adj phone) OR (web based) OR (text message) OR (text messaging) OR SMS</p> <p>AND</p> <p>Sexually Transmitted Diseases/ OR (sexually transmitted disease*) OR (sexually transmissible infection*) OR (sexually transmitted infection*) OR STI* OR STD* OR HIV OR (Human immunodeficiency virus) OR Chlamydia OR gonorrh?ea OR neisseria gonorrhoeae OR syphilis OR treponema pallidum</p> <p>AND</p> <p>Contact Tracing/ OR ((Partner or contact) adj notification) OR (partner tracing) OR ((partner or contact) adj treatment) OR ((partner or contact) adj testing) OR ((partner or contact) adj screening) OR ((partner or contact) adj management) OR ((partner or contact) adj services) OR (communicable disease control) OR (exposure notification)</p>
Ovid Embase	<p>Telemedicine/ OR Mhealth OR m-health OR e-notification* OR ((digital or mobile) adj health) OR on?line OR internet OR app OR application OR ((cellular or mobile or smart) adj phone) OR (web based) OR (text message) OR (text messaging) OR SMS</p> <p>AND</p> <p>Sexually Transmitted Disease/ OR (sexually transmitted disease*) OR (sexually transmissible infection*) OR (sexually transmitted infection*) OR STI* OR STD* OR HIV OR (Human immunodeficiency virus) OR Chlamydia OR gonorrh?ea OR neisseria gonorrhoeae OR syphilis OR treponema pallidum</p> <p>AND</p> <p>Contact Examination/ OR ((Partner or contact) adj notification) OR (partner tracing) OR ((partner or contact) adj treatment) OR ((partner or contact) adj testing) OR ((partner or contact) adj screening) OR ((partner or contact) adj management) OR ((partner or contact) adj services) OR (communicable disease control) OR (exposure notification)</p>

PsychInfo	<p>Telemedicine/ OR Mhealth OR m-health OR e-notification* OR ((digital or mobile) adj health) OR on?line OR internet OR app OR application OR ((cellular or mobile or smart) adj phone) OR (web based) OR (text message) OR (text messaging) OR SMS</p> <p>AND</p> <p>Sexually Transmitted Diseases/ OR (sexually transmitted disease*) OR (sexually transmissible infection*) OR (sexually transmitted infection*) OR STI* OR STD* OR HIV OR (Human immunodeficiency virus) OR Chlamydia OR gonorrh?ea OR (neisseria gonorrhoeae) OR syphilis OR (treponema pallidum)</p> <p>AND</p> <p>((Partner or contact) adj notification) OR ((Partner or contact) adj tracing) OR ((partner or contact) adj treatment) OR ((partner or contact) adj testing) OR ((partner or contact) adj screening) OR ((partner or contact) adj management) OR ((partner or contact) adj services) OR (communicable disease control) OR (exposure notification)</p>
Scopus	<p>(TITLE-ABS-KEY (telemedicine OR mhealth OR "m-health" OR "e-notification*" OR online OR internet OR app OR application OR "text message" OR "text messaging" OR sms) OR TITLE-ABS-KEY (((digital OR mobile) W/O health)) OR TITLE-ABS-KEY (((cellular OR mobile OR smart) W/O phone)) AND TITLE-ABS-KEY (("sexually transmitted disease*") OR ("sexually transmissible infection*") OR ("sexually transmitted infection*") OR sti* OR std* OR hiv OR ("human immunodeficiency virus") OR chlamydia OR gonorrhoea OR gonorrhoea OR ("neisseria gonorrhoeae") OR syphilis OR ("treponema pallidum")) AND TITLE-ABS-KEY (((partner OR contact) W/O (notification OR tracing OR treatment OR testing OR screening OR management OR services))) OR TITLE-ABS-KEY (("communicable disease control") OR ("exposure notification"))) AND PUBYEAR > 2009</p>
Web of Science	<p>Telemedicine OR Mhealth OR "m-health" OR "e-notification*" OR ((digital or mobile) NEAR/0 health) OR online OR internet OR app OR application OR ((cellular or mobile or smart) NEAR/0 phone) OR ("web based") OR ("text message") OR ("text messaging") OR SMS</p> <p>AND</p> <p>("sexually transmitted disease*") OR ("sexually transmissible infection*") OR ("sexually transmitted infection*") OR STI* OR STD* OR HIV OR ("Human immunodeficiency virus") OR Chlamydia OR gonorrhoea OR gonorrhoea OR "neisseria gonorrhoeae" OR syphilis OR "treponema pallidum" AND</p> <p>((partner OR contact) NEAR/0 (notification OR tracing OR treatment OR testing OR screening OR management OR services) OR ("communicable disease control") OR ("exposure notification"))</p>

CINAHL Plus	<p>Telemedicine OR Mhealth OR "m-health" OR "e-notification*" OR ((digital or mobile) NO health) OR online OR internet OR app OR application OR ((cellular or mobile or smart) NO phone) OR ("web based") OR ("text message") OR ("text messaging") OR SMS</p> <p>AND</p> <p>("sexually transmitted disease*") OR ("sexually transmissible infection*") OR ("sexually transmitted infection*") OR STI* OR STD* OR HIV OR ("Human immunodeficiency virus") OR Chlamydia OR gonorrhoea OR gonorrhoea OR "neisseria gonorrhoeae" OR syphilis OR "treponema pallidum" AND</p> <p>((partner OR contact) NO (notification OR tracing OR treatment OR testing OR screening OR management OR services) OR ("communicable disease control") OR ("exposure notification"))</p>
Cochrane Library (including Cochrane Central Register of Controlled Trials (CENTRAL), Cochrane Database of Systematic Reviews, Cochrane Methodology Register)	<p>Telemedicine/ OR Mhealth OR "m-health" OR e-notification* OR ((digital or mobile) NEAR/0 health) OR on?line OR internet OR app OR application OR ((cellular or mobile or smart) adj phone) OR "web based" OR "text message" OR "text messaging" OR SMS</p> <p>AND</p> <p>Sexually Transmitted Diseases/ OR (sexually transmitted disease*) OR sexually transmissible infection* OR sexually transmitted infection* OR STI* OR STD* OR HIV OR "Human immunodeficiency virus" OR Chlamydia OR gonorrh?ea OR "neisseria gonorrhoeae" OR syphilis OR "treponema pallidum"</p> <p>AND</p> <p>Contact tracing/ OR ((partner OR contact) NEAR/0 (notification OR tracing OR treatment OR testing OR screening OR management OR services) ("communicable disease control") OR ("exposure notification"))</p>
NHS Evidence	<p>(Telemedicine OR Mhealth OR "m health" OR "e notification*" OR "digital health" OR "mobile health" OR online OR internet OR app OR application OR "cellular phone" or "mobile phone" OR "smart phone" OR "web based" OR "text message" OR "text messaging" OR SMS)</p> <p>AND</p> <p>("sexually transmitted disease*" OR "sexually transmissible infection*" OR "sexually transmitted infection*" OR STI* OR STD* OR HIV OR "Human immunodeficiency virus" OR Chlamydia OR gonorrhoea OR gonorrhoea OR "neisseria gonorrhoeae" OR syphilis OR "treponema pallidum")</p> <p>AND</p> <p>("partner notification" OR "partner tracing" OR "partner treatment" OR "partner testing" OR "partner screening" OR "partner management" OR "partner services" OR "contact notification" OR "contact tracing" OR "contact treatment" OR "contact testing" OR "contact screening" OR "contact management" OR "contact services" OR "communicable</p>

	disease control" OR "exposure notification")
--	--

Appendix C: Mixed Methods Appraisal Tool

Qualitative Studies								
Study	Are there clear research questions?	Do the collected data allow to address the research questions?	Is the qualitative approach appropriate to answer the research question?	Are the qualitative data collection methods adequate to address the research question?	Are the findings adequately derived from the data?	Is the interpretation of results sufficiently substantiated by data?	Is there coherence between qualitative data sources, collection, analysis and interpretation?	Comments
Balán (2020)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Contesse (2019)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Gkatzidou et al. (2013)	Yes	Yes	Yes	Yes	Yes	Can't tell	Can't tell	Quoted data not provided, unable to comment on interpretation.
Hopkins et al. (2010)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Lessard (2019)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Randomised Controlled Trials								
Study	Are there clear research questions?	Do the collected data allow to address the research	Is randomisation appropriately performed?	Are the groups comparable at baseline?	Are there complete outcome data?	Are outcome assessors blinded to the intervention provided?	Did the participants adhere to the assigned intervention?	Comments

Study	Are there clear research questions?	Do the collected data allow to address the research questions?	Are the participants representative of the target population?	Are measurements appropriate regarding both the outcome and intervention (or exposure)?	Are there complete outcome data?	Are the confounders accounted for in the design and analysis?	During the study period, is the intervention administered (or exposure occurred) as intended?	Comments
Clark et al. (2018)	Yes	Yes	Yes	Yes	Yes	Can't tell	Yes	Blinding is not discussed for data collection or analysis.
Non-Randomised Studies								
Estcourt et al. (2017)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Hightow-Weidman (2014)	Yes	Yes	Yes	Yes	Yes	Can't tell	Yes	Data extracted from existing sources, less controlled than primary collection. Confounders not discussed.
Hightow-Weidman et al. (2014)	Yes	Yes	Yes	Yes	Yes	Can't tell	Yes	
Mobley et al. (2018)	Yes	Yes	Yes	Yes	Yes	Can't tell	Yes	Data extracted from existing sources, less controlled than primary collection. Confounders not discussed.
Pennise et al. (2015)	Can't tell	Can't tell	Yes	Yes	Can't tell	Can't tell	Can't tell	Data extracted from existing sources, less

								controlled than primary collection.
Udeagu et al. (2014)	Yes	Yes	Yes	Yes	Yes	Can't tell	Yes	Data extracted from existing sources, less controlled than primary collection. Confounders not discussed.
Quantitative Descriptive Studies								
Study	Are there clear research questions?	Do the collected data allow to address the research questions?	Is the sampling strategy relevant to address the research question?	Is the sample representative of the target population?	Are the measurements appropriate?	Is the risk of nonresponse bias low?	Is the statistical analysis appropriate to answer the research question?	Comments
Carnicer-Pont et al. (2015)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Clark et al. (2014)	Yes	Yes	Yes	Yes	Yes	Can't tell	Yes	No information for people who declined participation.
Contesse et al. (2020)	Yes	Yes	Yes	Yes	Yes	Can't tell	Yes	No information for people who declined participation.
Götz (2014)	Yes	Yes	Yes	No	Yes	Can't tell	Yes	
Htaik (2022)	Yes	Yes	Yes	Yes	Yes	Can't tell	Yes	
John (2020)	Yes	Yes	Yes	Yes	Yes	Can't tell	Yes	
Mokgatle (2022)	Yes	Yes	Yes	No	Yes	Can't tell	Yes	
Mokgatle (2021)	Yes	Yes	Yes	No	Yes	Can't tell	Yes	

Mokgatle (2020)	Yes	Yes	Yes	No	Yes	Can't tell	Yes	
van Rooijen et al. (2018)	Yes	Yes	Yes	Yes	Yes	No	Yes	
Wang et al. (2016)	Yes	Yes	Yes	Yes	Yes	Can't tell	Yes	No demographics for people who declined participation.
Willetts (2018)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Mixed Methods Studies								
Study	Are there clear research questions?	Do the collected data allow to address the research questions?	Is there an adequate rationale for using a mixed methods design to address the research question?	Are the different components of the study effectively integrated to answer the research question?	Are the outputs of the integration of qualitative and quantitative components adequately interpreted?	Are divergences and inconsistencies between quantitative and qualitative results adequately addressed?	Do the different components of the study adhere to the quality criteria of each tradition of the methods involved?	Comments
Guy et al. (2016)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	
Hunter et al. (2014)	Can't tell	Can't tell	Can't tell	Can't tell	Can't tell	Can't tell	Can't tell	No clear research question, so cannot assess the data collected for this. Methodology not discussed or rationalised, unclear whether pre-planned

								qualitative interview. Qualitative quoted data not provided, unable to comment on interpretation. Data extracted from existing sources, less controlled than primary collection.
Kutner (2021)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	